Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib + epcoritamab versus R-(mini)-CHOP in DLBCL-type Richter transformation
NL-OMON61471Phase 3Not yet recruiting
- Sponsor
- University of Cologne
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib, epcoritamab, rituximab, cyclophosphamide, doxorubicin and 2 more in Diffuse Large B-Cell Lymphoma Richter Transformation, sponsored by University of Cologne. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
pirtobrutinibepcoritamabrituximabcyclophosphamidedoxorubicin
03
Conditions
Diffuse Large B-Cell Lymphoma Richter Transformation
Beyond the preview
Go deeper on NL-OMON61471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61471.